Nuvation Bio vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Nuvation Bio Inc (NUVB)

Q3 202626 Jun – 13 Aug 2026

▲3

Nuvation Bio: IBTROZI Sales Jump, UK Filing Advances, Cash Strengthened

IBTROZI revenue grows 25% as first-line use takes off Nuvation Bio reported Q2 2026 IBTROZI net product revenue of $23.2 million, up 25% from the prior quarter. About 160 new patients started treatment, and 85% of those were first-line, up from 30% at launch. This shows the drug is being adopted earlier in treatment, which supports future sales growth and lifts the stock.
This is the core commercial driver showing real revenue growth and broader adoption, directly supporting the bull case.
UK regulator accepts taletrectinib marketing application The UK drug regulator validated Nuvation Bio partner Eisai's marketing application for taletrectinib in ROS1-positive lung cancer. This follows earlier validation in Europe and adds to approvals already in the US, Japan, and China. Each new market expands the potential patient pool and future royalty or sales revenue, which is positive for the stock.
This is a new regulatory milestone that expands the drug's global reach and future revenue potential.
Safusidenib brain tumor program expands with strong data Nuvation Bio announced an expanded clinical plan for safusidenib in IDH1-mutant glioma, with updated Phase II data showing a 52% response rate and 79% three-year progression-free survival. The company is adding a randomized Phase III trial and a Phase II study in earlier-stage patients. This pipeline progress increases the chance of a future second approved product, supporting the stock.
This is a new pipeline expansion with encouraging data that adds long-term value beyond the current commercial drug.
Convertible notes raise cash but dilute shareholders Nuvation Bio raised about $279 million net from convertible notes due 2032 and ended June with $661 million in cash. The money funds UK and other filings plus glioma studies and should last through profitability. However, the notes can later convert to shares, diluting existing owners, and the company still posted a $62.8 million quarterly net loss.
This explains the financing that supports operations but also the dilution and losses that weigh on the stock.

July 202626 Jun – 13 Aug 2026

▲3

Nuvation Bio: IBTROZI Sales Jump, UK Filing Advances, Cash Strengthened

IBTROZI revenue grows 25% as first-line use takes off Nuvation Bio reported Q2 2026 IBTROZI net product revenue of $23.2 million, up 25% from the prior quarter. About 160 new patients started treatment, and 85% of those were first-line, up from 30% at launch. This shows the drug is being adopted earlier in treatment, which supports future sales growth and lifts the stock.
This is the core commercial driver showing real revenue growth and broader adoption, directly supporting the bull case.
UK regulator accepts taletrectinib marketing application The UK drug regulator validated Nuvation Bio partner Eisai's marketing application for taletrectinib in ROS1-positive lung cancer. This follows earlier validation in Europe and adds to approvals already in the US, Japan, and China. Each new market expands the potential patient pool and future royalty or sales revenue, which is positive for the stock.
This is a new regulatory milestone that expands the drug's global reach and future revenue potential.
Safusidenib brain tumor program expands with strong data Nuvation Bio announced an expanded clinical plan for safusidenib in IDH1-mutant glioma, with updated Phase II data showing a 52% response rate and 79% three-year progression-free survival. The company is adding a randomized Phase III trial and a Phase II study in earlier-stage patients. This pipeline progress increases the chance of a future second approved product, supporting the stock.
This is a new pipeline expansion with encouraging data that adds long-term value beyond the current commercial drug.
Convertible notes raise cash but dilute shareholders Nuvation Bio raised about $279 million net from convertible notes due 2032 and ended June with $661 million in cash. The money funds UK and other filings plus glioma studies and should last through profitability. However, the notes can later convert to shares, diluting existing owners, and the company still posted a $62.8 million quarterly net loss.
This explains the financing that supports operations but also the dilution and losses that weigh on the stock.

Latest26 Jun – 13 Aug 2026

▲3

Nuvation Bio: IBTROZI Sales Jump, UK Filing Advances, Cash Strengthened

IBTROZI revenue grows 25% as first-line use takes off Nuvation Bio reported Q2 2026 IBTROZI net product revenue of $23.2 million, up 25% from the prior quarter. About 160 new patients started treatment, and 85% of those were first-line, up from 30% at launch. This shows the drug is being adopted earlier in treatment, which supports future sales growth and lifts the stock.
This is the core commercial driver showing real revenue growth and broader adoption, directly supporting the bull case.
UK regulator accepts taletrectinib marketing application The UK drug regulator validated Nuvation Bio partner Eisai's marketing application for taletrectinib in ROS1-positive lung cancer. This follows earlier validation in Europe and adds to approvals already in the US, Japan, and China. Each new market expands the potential patient pool and future royalty or sales revenue, which is positive for the stock.
This is a new regulatory milestone that expands the drug's global reach and future revenue potential.
Safusidenib brain tumor program expands with strong data Nuvation Bio announced an expanded clinical plan for safusidenib in IDH1-mutant glioma, with updated Phase II data showing a 52% response rate and 79% three-year progression-free survival. The company is adding a randomized Phase III trial and a Phase II study in earlier-stage patients. This pipeline progress increases the chance of a future second approved product, supporting the stock.
This is a new pipeline expansion with encouraging data that adds long-term value beyond the current commercial drug.
Convertible notes raise cash but dilute shareholders Nuvation Bio raised about $279 million net from convertible notes due 2032 and ended June with $661 million in cash. The money funds UK and other filings plus glioma studies and should last through profitability. However, the notes can later convert to shares, diluting existing owners, and the company still posted a $62.8 million quarterly net loss.
This explains the financing that supports operations but also the dilution and losses that weigh on the stock.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.